SCHEMBL847862

SCHEMBL847862

COC(=O)c1cc(N)ccc1Br

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.61
TTBK1 Q5TCY1 1/20 0.48
TTBK2 Q6IQ55 1/20 0.48
ALDH1A1 P00352 5/20 0.47
KDM4E B2RXH2 5/20 0.47
HSD17B10 Q99714 3/20 0.47
MAPT P10636 3/20 0.47
HPGD P15428 2/20 0.47
GLA P06280 2/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
ATM Q13315 1/20 0.47
CFTR P13569 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C19 P33261 2/20 0.47
KMT2A Q03164 2/20 0.47
CYP3A4 P08684 1/20 0.47
PKM P14618 1/20 0.47
ABL1 P00519 1/20 0.46
ALOX15 P16050 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29608693 1.00 GAA (0.61) GAATTBK1TTBK2ALDH1A1KDM4E
SCHEMBL29426539 0.85 GAA (0.66) GAAALDH1A1KDM4EHSD17B10MAPT
SCHEMBL3172089 0.85 GAA (0.66) GAAALDH1A1KDM4EHSD17B10MAPT
SCHEMBL1403643 0.82 GAA (0.72) GAAALDH1A1KDM4EHSD17B10MAPT
SCHEMBL861495 0.81 PTPN2 (0.54) GAATTBK1TTBK2ALDH1A1HSD17B10
SCHEMBL6168887 0.81 GAA (0.66) GAAALDH1A1KDM4EHSD17B10MAPT
SCHEMBL7623605 0.81 GAA (0.70) GAAALDH1A1KDM4EHSD17B10MAPT
SCHEMBL9705197 0.81 GAA (0.65) GAAALDH1A1KDM4EHSD17B10MAPT
SCHEMBL10923552 0.81 CA12 (0.46) GAAALDH1A1KDM4EHSD17B10MAPT
SCHEMBL31249571 0.81 LMNA (0.54) GAAALDH1A1KDM4EHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026098560-A2 BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2026-05-15 WO disclosed
US-12577254-B2 Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors Signal Rx Pharmaceuticals, Inc. 2026-03-17 US disclosed
US-20260008791-A1 CHEMICAL COMPOUNDS BORAH INC (US) 2026-01-08 US disclosed
US-12358932-B2 Chemical compounds BORAH, INC. (US) 2025-07-15 US disclosed
WO-2025082467-A1 IMMUNOMODULATORS 成都先导药物开发股份有限公司 2025-04-24 WO disclosed
US-12239630-B2 Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2025-03-04 US disclosed
CN-115068468-B Carboxylic aromatic amides as bradykinin B1 receptor antagonists 拜耳制药股份公司 2025-02-25 CN disclosed
EP-4499630-A1 BCL-XL INHIBITORS BeiGene, Ltd. (KY) 2025-02-05 EP disclosed
US-20250034128-A1 BCL-XL INHIBITORS BEIGENE, LTD. (KY) 2025-01-30 US disclosed
CN-119343143-A Boron-containing pyrimidine compounds, compositions containing them, methods and uses thereof 博拉公司 2025-01-21 CN disclosed
EP-1178969-A1 GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS JAMES BLACK FOUNDATION LIMITED (GB) 2002-02-13 EP disclosed
CN-1325385-A Gastrin and cholecystokinin receptor ligands BLACK JAMES FOUNDATION (GB) 2001-12-05 CN disclosed
US-6319918-B1 FOR LYMPHOMA OR SOLID TUMORS TREATMENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-11-20 US disclosed
CN-1290165-A Benzothiazole Protein tyrosine kinase inhibitors BRISTOL MYERS SQUIBB CO (US) 2001-04-04 CN disclosed
EP-1037632-A1 BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2000-09-27 EP disclosed
US-6100272-A Tetracyclic spiro compounds as 5HT1B receptor antagonists SMITHKLINE BEECHAM P.L.C. (GB) 2000-08-08 US disclosed
WO-2000027823-A1 GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS JAMES BLACK FOUNDATION LIMITED (GB) 2000-05-18 WO disclosed
WO-1999024035-A1 BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 1999-05-20 WO disclosed
EP-0888358-A1 PIPERIDINE DERIVATIVES SMITHKLINE BEECHAM PLC (GB) 1999-01-07 EP disclosed
WO-1997034901-A1 PIPERIDINE DERIVATIVES SMITHKLINE BEECHAM P.L.C. (GB) 1997-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260008791-A1 CHEMICAL COMPOUNDS JAK3, JAK2, JAK1 GAA 2124/4885TTBK1 1072/4885TTBK2 956/4885
US-12239630-B2 Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor BDKRB1, BDKRB2, HCAR1 GAA 1745/4885TTBK1 1970/4885TTBK2 2485/4885
US-20250034128-A1 BCL-XL INHIBITORS BCL2, BCL2L1, BCL2L10 GAA 587/4885TTBK1 807/4885TTBK2 1042/4885
US-12577254-B2 Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors CHEK1, CDK1, CDK3 GAA 4429/4885TTBK1 536/4885TTBK2 815/4885
US-12358932-B2 Chemical compounds PDE4A, PDE4B, SYK GAA 880/4885TTBK1 912/4885TTBK2 787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.